NCCM
SUPN icon

Nine Chapters Capital Management’s Supernus Pharmaceuticals SUPN Stock Holding History

Nine Chapters Capital Management’s Portfolio SUPN Stock Details SUPN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q3 		– Sell
-34,600
Closed -$588K – 1164
2015
Q2 		$588K Buy
+34,600
New +$492K 0.05% 515
2014
Q4 		– Sell
-26,200
Closed -$228K – 1168
2014
Q3 		$228K Buy
+26,200
New +$237K 0.02% 809

Other funds holding SUPN

NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
RIM
Ranger Investment Management Dallas, Texas $1.38B AUM 24.55% 1-Year Est. Return
ACM
Apex Capital Management Dayton, Ohio $4.54B AUM 1.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GT
Glenmede Trust Philadelphia, Pennsylvania $20.4B AUM
MRM
Michael R. Murphy $255M AUM 0.87% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nine Chapters Capital Management's SUPN Position: Q3 2015 in Review

Nine Chapters Capital Management sold out of Supernus Pharmaceuticals (SUPN) in Q3 2015, closing a stake of 34,600 shares — an estimated $588K sold.

Nine Chapters Capital Management first reported a position in SUPN in Q3 2014 and held it in 2 quarters. The position peaked at $588K in Q2 2015. 185 funds tracked by Wall St. Rank hold SUPN as of Q3 2015.

  • Nine Chapters Capital Management reported no remaining Supernus Pharmaceuticals position as of Q3 2015 after selling out during the quarter.
  • Nine Chapters Capital Management sold 34,600 Supernus Pharmaceuticals shares in Q3 2015, an estimated $588K.
  • Nine Chapters Capital Management first reported a position in Supernus Pharmaceuticals in Q3 2014 and held it in 2 quarters.
  • Nine Chapters Capital Management's Supernus Pharmaceuticals position peaked at $588K in Q2 2015.
  • 185 funds tracked by Wall St. Rank held Supernus Pharmaceuticals as of Q3 2015.

Based on Nine Chapters Capital Management's 13F filing for Q3 2015, filed 16 Nov 2015.